Clinical Trial Update: Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure [Phase 2]

View source ↗

Summary

A Phase 2 trial of a daratumumab-based regimen for newly diagnosed multiple myeloma with kidney failure has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Renal Failure

Drugs mentioned

• Daratumumab (Darzalex) (daratumumab)

Snippet

Sponsor: Emory University | Conditions: Plasma Cell Myeloma, Renal Failure | Phase 2 | Status: TERMINATED